Among the features of the Part D structure is a federal reinsurance program in which, when a beneficiary reaches the catastrophic threshold in a given year, the government subsidizes 80% of remaining spending for the year. Part D plans pay 15%, and patients pay 5% in this scenario.
The rising cost of prescription drugs is an issue that impacts all American patients, and while a variety of policy proposals have been brought forward to address this issue—from the Trump administration’s proposal to link US drug prices with an international index to House Democrats’ proposals to allow Medicare to negotiate prices—a group of economists and policy experts have written a perspective article calling for changes to Part D that would see plans taking on greater risk.
Among the features of the Part D structure is a federal reinsurance program in which, when a beneficiary reaches the catastrophic threshold in a given year, the government subsidizes 80% of remaining spending for the year. Part D plans pay 15%, and patients pay 5% in this scenario.
According to the authors, in the first years of Part D, this reinsurance approach “seemed reasonable,” but the design has not kept pace with the market, particularly as specialty drugs have gained a prominent place in the healthcare landscape. Today, they write, reinsurance subsidies reach approximately $43 billion each year.
“As reinsurance spending grows disproportionately, plans bear less and less risk as a share of total spending,” say the authors. “This situation calls into question what is being gained through the use of private plans.”
Also of note is the fact that drug makers are largely responsible for contributions to address the Part D coverage gap, or “donut hole,” and plans have little liability for addressing costs in this phase. Federal policy that holds that Part D plans must cover nearly all drugs in 6 protected classes also limits plans’ ability to manage costs.
“The net result is that, today, Part D plans are actually responsible for only about 34% of total prescription-drug spending,” the authors write, while commercial plans paid an average of 85% of total drug costs in 2016.
The authors argue that Part D should be redesigned in order to relieve the disproportionate burden placed on the government and to make plans shoulder more risk. Any reforms should also include protections for beneficiaries, like out-of-pocket spending caps, and the government should be able to use its recouped funds to help keep premiums low.
“It took policymakers 40 years to add an outpatient prescription-drug benefit to the Medicare program. Let’s hope we don’t have to wait 40 more to modernize Part D,” write the authors.
Reference
Trish EE, Ginsburg PB, Joyce GF, Goldman DP. Who pays in Medicare Part D? Giving plans more skin in the game [published online November 20, 2019]. N Engl J Med. doi: 10.1056/NEJMp1912357.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.